Pasireotide ditrifluoroacetate

帕瑞肽二三氟乙酸酯

Pasireotide ditrifluoroacetate

P658895-5mg

5mg

≥99%

-20°C储存,干燥

超低温冰袋运输

Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5 , pK i =8.2/9.0/9.1/ Appearance:Solid IC50& Target:pKi: 8.2 (sst1), 9.0 (sst2), 9.1 (sst3), In Vitro:Pasireotide ditrifluoroacetate exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pK i =8.2/9.0/9.1/ In Vivo:Pasireotide ditrifluoroacetate (160mg/kg/mouth; s.c. for 4 months) significantly decreases the serum insulin, increases serum glucose, reduces the tumor size and increases apoptosis in Pdx1-Cre. Pasireotide ditrifluoroacetate (2-50 μg/kg; s.c. twice Biological Activity:Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5 , pK i =8.2/9.0/9.1/

C62H68F6N10O13

1275.25 g/mol

O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.NCCCC[C@@H](C(N[C@H]1CC2=CC=C(C=C2)OCC3=CC=CC=C3)=O)NC([C@H](NC([C@H](C4=CC=CC=C4)NC([C@H]5N(C([C@H](CC6=CC=CC=C6)NC1=O)=O)C[C@H](OC(NCCN)=O)C5)=O)=O)CC7=CNC8=C7C=CC=C8)=O

DMSO : 100 mg/mL (78.42 mM; Need ultrasonic) H2O : 33.33 mg/mL (26.14 mM; Need ultrasonic)